| Literature DB >> 33158510 |
Sandra Russo1, Joan L Walker2, Jay W Carlson3, Jeanne Carter4, Leigh C Ward5, Allan Covens6, Edward J Tanner7, Jane M Armer8, Sheila Ridner9, Sandi Hayes10, Alphonse G Taghian11, Cheryl Brunelle12, Micael Lopez-Acevedo13, Brittany A Davidson14, Mark V Schaverien15, Sharad A Ghamande16, Michael Bernas17, Andrea L Cheville18, Kathleen J Yost19, Kathryn Schmitz20, Barbara Coyle21, Jeannette Zucker22, Danielle Enserro23, Stephanie Pugh24, Electra D Paskett25, Leslie Ford26, Worta McCaskill-Stevens27.
Abstract
Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials. Published by Elsevier Inc.Entities:
Keywords: Gynecologic cancers; Lymphedema; Oncologic surgical treatment; Patient reported outcomes; Quantitative measurements
Mesh：
Year: 2020 PMID： 33158510 PMCID： PMC7946397 DOI： 10.1016/j.ygyno.2020.10.026
Source DB: PubMed Journal: Gynecol Oncol ISSN： 0090-8258 Impact factor: 5.482